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Abstract
Background: The 4T1 mouse mammary tumor cell line is one of only a few breast cancer models
with the capacity to metastasize efficiently to sites affected in human breast cancer. Here we
describe two 4T1 cell lines modified to facilitate analysis of tumor growth and metastasis and
evaluation of gene function in vivo. New information regarding the involvement of innate and
acquired immunity in metastasis and other characteristics of the model relevant to its use in the
study of late stage breast cancer are reported.
Methods: The lines were engineered for stable expression of firefly luciferase to allow tracking
and quantitation of the cells in vivo. Biophotonic imaging was used to characterize growth and
metastasis of the lines in vivo and an improved gene expression approach was used to characterize
the basis for the metastatic phenotype that was observed.
Results: Growth of cells at the primary site was biphasic with metastasis detected during the
second growth phase 5–6 weeks after introduction of the cells. Regression of growth, which
occurred in weeks 3–4, was associated with extensive necrosis and infiltration of leukocytes.
Biphasic tumor growth did not occur in BALB/c SCID mice indicating involvement of an acquired
immune response in the effect. Hematopoiesis in spleen and liver and elevated levels of circulating
leukocytes were observed at week 2 and increased progressively until death at week 6–8. Gene
expression analysis revealed an association of several secreted factors including colony stimulatory
factors, cytokines and chemokines, acute phase proteins, angiogenesis factors and ECM modifying
proteins with the 4T1 metastatic phenotype. Signaling pathways likely to be responsible for
production of these factors were also identified.
Conclusion: The production of factors that stimulate angiogenesis and ECM modification and
induce hematopoiesis, recruitment and activation of leukocytes suggest that 4T1 tumor cells play
a more direct role than previously appreciated in orchestrating changes in the tumor environment
conducive to tumor cell dissemination and metastasis. The new cell lines will greatly facilitate the
study of late stage breast and preclinical assessment of cancer drugs and other therapeutics
particularly those targeting immune system effects on tumor metastasis.
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Background
While investigation of the molecular basis of tumor
metastasis has in large part focused on proliferation and
dissemination of tumor cells from the primary tumor,
later events that occur at sites of metastasis are most often
responsible for patient mortality and morbidity. From a
clinical standpoint, an understanding of the disease at
metastatic sites is paramount since the number of breast
cancer patients with detectable or occult metastases at the
time of diagnosis is substantial and most patients will
develop metastatic lesions at some point during the
course of the disease. Metastasis is generally treated as a
systemic disease with chemotherapy and/or radiation
even though factors involved in establishment and growth
of metastatic lesions differ from one site to the next and
may differ in response to therapeutics. While currently
used therapeutic regimens are capable of slowing the pro-
gression of metastatic disease, rarely is it possible to stop
or reverse the process. Treatments that address the nature
of metastatic disease at the site of metastasis could provide
more effective therapeutic results for patients afflicted
with the later stages of the disease.
A major impediment for the study of metastasis has been
the availability of suitable models that faithfully represent
the metastatic process as it occurs in vivo. Xenograft mod-
els in which human tumor cells are introduced into
immunocompromised mice have been used extensively
for the study of tumor growth and metastasis and to vali-
date specific gene products as drug targets for cancer ther-
apy. While some human xenograft models can
approximate primary tumor growth in mice, replication
of tumor metastasis is more problematic [1-3]. Human
tumor cells generally metastasize poorly in mice and
when metastasis does occur, unexpected metastatic char-
acteristics are often observed. In contrast, murine tumor
cell models often metastasize more effectively and display
metastatic characteristics more similar to those observed
in cancer patients [4]. Given the importance of microenvi-
ronment and tumor-host interactions in tumor cell
behavior, this is not surprising. Syngeneic mouse models
such as the 4T1 model described here also have the impor-
tant advantage of allowing analyses to be carried out in
animals with normal immune function. Because the
immune system plays an important role in the develop-
ment and progression of cancer, models that can be used
in immunocompetent mice are essential for analysis of
cancer progression and evaluation of therapeutics for can-
cer treatment.
The 4T1 mammary carcinoma cell line was originally iso-
lated by Fred Miller and coworkers at the Karmanos Can-
cer Institute [5,6]. Its use has increased in recent years
because of its high propensity to metastasize to bone and
other sites [7,8]. When introduced orthotopically, 4T1 is
capable of metastasis to several organs affected in breast
cancer including lungs, liver and brain, as well as bone
[7,9-11]. 4T1 sibling cell lines with different metastatic
properties have been isolated and characterized. These
lines were isolated from the same spontaneous arising
BALB/c mammary tumor [5,6] but appear to have fol-
lowed divergent pathways for acquisition of their meta-
static phenotypes [12].
We have modified the 4T1 cell line for optimal use as a
model for the study of late stage breast cancer. A modified
line (4T1-12B) expressing high levels of firefly luciferase
to allow non-invasive longitudinal imaging of in vivo
growth and metastasis was isolated. A similar line (4T1-
1V) was further modified by insertion of a FLP recombi-
nase target (FRT) site into the 4T1 genome. The FRT site
facilitates rapid generation of genetically modified iso-
genic cell lines for investigation of effector gene function.
The extent and kinetics of metastasis to organs affected in
human breast cancer indicated extensive colonization of
lungs and liver in most animals within a six week period
with lower efficiency of metastasis to bone, brain and
other sites. Innate and adaptive immune responses were
shown to play important roles in growth and metastasis of
the lines in BALB/c mice. Analysis of gene expression com-
paring 4T1 and two of its non-metastatic sibling cell lines
suggested prominent roles for several signaling pathways
and secreted factors in directing microenvironmental
changes within the tumor leading to tumor cell dissemi-
nation and metastasis.
Methods
Materials
The luciferase-containing pGL3-Control vector was
obtained from Promega. The pKO-puro vector was from
Stratagene. The pSHAG-1 vector was provided by Dr. G.
Hannon at Cold Spring Harbor Laboratory. Other vectors
including pcDNA5/FRT, pOG44, pFRT/lacZeo, and the
Gateway Vector Conversion System Reading Frame Cas-
sette C.1 were obtained from Invitrogen. Dulbecco's mod-
ified Eagle's medium (DMEM), Dulbecco's phosphate-
buffered saline without calcium and magnesium (PBS),
fetal bovine serum (FBS), newborn calf serum (NCS),
non-essential amino acids (NEAA), penicillin, streptomy-
cin and lipofectamine PLUS reagent were from Invitrogen.
Puromycin and hygromycin were from Sigma. Luciferin
was obtained from Caliper Life Sciences.
Cell culture
The 67NR, 168FARN and 4T1 mouse mammary tumor
cell lines were obtained from Dr. Fred Miller at Karmanos
Cancer Institute. Cells were cultured in high glucose
DMEM supplemented 5% FBS, 5% NCS, NEAA and anti-
biotics (100 units/ml penicillin and 100 μg/ml strepto-
mycin) at 37°C in a humidified atmosphere containingBMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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5% CO2. Except where indicated, analyses were per-
formed on same passage cells within 2 weeks after thaw-
ing. All cell lines used in the study were tested and shown
to be free of mycoplasma and viral contamination.
Expression of luciferase and puromycin resistance in 4T1 
cell lines
4T1 cells were cotransfected with firefly luciferase-con-
taining pGL-3-Control vector and the puromycin resist-
ance vector, pKO-puro, at a ratio of 10:1 using
Lipofectamine PLUS as described by the vendor [Invitro-
gen]. Transfected cells were selected with puromycin at a
final concentration of 10 μg/ml and several colonies were
picked and expanded for analysis. Colonies displaying the
highest level of luciferase expression were injected into
mammary fat pads of female BALB/c mice and imaged 6
weeks later before and after sacrifice and necropsy, as
described below. One cell line, designated 4T1-12B,
which retained high level expression of luciferase in the
absence of puromycin and displayed metastatic properties
similar to the parental line, was retained for further anal-
ysis and modification. Sublines were obtained from the
4T1-12B line by limiting dilution cloning.
Incorporation of FRT site into 4T1 cell line
To introduce the FLP recombinase target (FRT) site in the
4T1 genome, cells were transfected with pFRT/lacZeo
using lipofectamine PLUS and selected with 100 μg/ml
zeocin. Colonies were picked and expanded and six clonal
lines with a single integration of the vector, as determined
by Southern blotting, were identified. The expanded lines
were analyzed for efficiency of transfection and targeting
and for in vivo tumor growth and metastasis. One line,
designated 4T1-1V, displayed growth and metastatic char-
acteristics similar to the parental 4T1 line and efficient
transfection and targeting to the FRT site with pcDNA5/
FRT (Invitrogen) and was retained for further analysis.
Construction of shRNA targeting vector
The pcDNA5/FRT targeting vector was modified to allow
transfer of the shRNA expression cassettes from pSHAG-
type shRNA expression vectors [13] to the pcDNA5/FRT
vector by Gateway site-specific recombination. Resulting
vectors can then be used to target shRNA expression cas-
settes to FRT sites in 4T1-1V and other FRT-containing cell
lines for creation of isogenic cell lines. A Gateway cloning
site was inserted into the vector by blunt end ligation of
Reading Frame Cassette C.1 (Invitrogen) into the vector's
Bgl II site.
Knockdown of luciferase with shRNA targeting vector
To test the efficacy of the construct, an empty expression
cassette and a cassette encoding a previously tested luci-
ferase shRNA [13] were transferred to the modified
pcDNA5/FRT from corresponding pSHAG-1 vectors. The
4T1-1V cells were then cotransfected with each construct
and pOG44 vector at a ratio of 1:10 using Lipofectamine
PLUS. Transfected cells were selected with hygromycin B
at a final concentration of 200 μg/ml. The pOG44 vector
encodes FLP recombinase which directs insertion of the
modified pcDNA5/FRT targeting vector into the cell's FRT
site; hygromycin B resistance is conferred upon insertion
of the vector into the site.
Expanded clones of hygromycin B resistant cells as well as
resistant cell pools from each transfection were then
assayed for luciferase activity using a Turner Designs
Model TD-20/20 Luminometer.
Biophotonic imaging of animals and organs
Luciferase-expressing cell lines were plated at 40% conflu-
ency and cultured for 24 h. The cells were then
trypsinized, washed, and resuspended in DMEM at 107
cells/ml and kept on ice before injection. Aliquots (100
μl) of the cells were injected into the no. 4 or no. 9 fatpad
of 4–6 week old female BALB/c, athymic BALB/c nude or
BALB/c SCID mice using a 26-gauge needle. Only cell
preparations with viability > 97%, as determined by
Trypan Blue exclusion, were used for injection.
At various times up to 6 weeks, animals were injected
intraperitoneally with 100 μl of D-luciferin (10 mg/ml) in
PBS, and after 10 min, imaged under anesthesia with
2.5% isofluorane in a Xenogen IVIS 200 biophotonic
imager. At experimental endpoints, luciferin-injected ani-
mals were sacrificed and organs and hind limbs were
removed and imaged within 15 minutes after injection.
Luminescence is expressed as photons/sec/ROI (region of
interest) minus background luminescence for a similarly
sized region. All experiments with animals were carried
out according to guidelines for the care and use of experi-
mental animals and were approved by the Tufts University
Institutional Animal Care and Use Committee.
Chip hybridizations and analysis of expression data
Biotin-labeled cRNAs were prepared from 250 ng of total
RNA using Ambion's TotalPrep RNA Amplification Kit.
Chip hybridizations, washing, Cy3-streptavidin (Amer-
sham Biosciences) labeling, and scanning were performed
on an Illumina BeadStation 500 platform using reagents
and protocols provided by the manufacturer. cRNA sam-
ples were hybridized to Illumina MouseRef-8 BeadChips
which cover 24,048 RefSeq transcripts. The manufactur-
ing principle of randomly distributing large populations
of oligonucleotide-coated beads across the available posi-
tions on the chip enables 30 intensity measurements per
feature on average, and produces quantitative results
closely matching those obtained by Q-PCR [14].BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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Biotin-labeled cRNAs were prepared from 3 biological
replicates of cultured 4T1, 67NR and 168FARN cells for
hybridization to the chips. Cells were plated at 5 × 105
cells in 10 cm culture dishes and after 3 days, when the
cells had reached confluence, the medium was changed
and the cells were cultured for an additional 24 hours.
Total RNA was isolated using the Absolutely RNA Kit from
Stratagene and checked for integrity using an Agilent Lab-
on-a-Chip Bioanalyzer.
Initial analysis of the data was carried out using Illumina's
BeadStudio software. Raw data for each sample were back-
ground-subtracted and normalized using the "cubic
spline" algorithm. Further statistical analysis of the data
was carried out using programs associated with BRB Array
Tools [15]. Differentially expressed genes for 4T1 samples
relative to 67NR and 168FARN samples were determined
separately with the Class Comparison program using the
random variance model and a p value of 0.0001. Signals
less than 10 were set to 10 to eliminate the inaccuracy of
analyzing genes expressed at near background levels from
being scored as differentially expressed. Genes that dif-
fered significantly (p < 0.0001) by > 2-fold for both com-
parisons (4T1/67NR and 4T1/168FARN) were considered
those associated with the metastatic phenotype of the 4T1
cell line. Because of the high level of reproducibility that
was achieved, a relatively high level of stringency (p <
0.0001) was chosen for selection of significant differ-
ences. As described in RESULTS, this permitted a very low
level of false positives with minimal loss of true positives.
Histochemistry and hematological analysis
Standard H & E staining of paraffin embedded tissue was
used for histological examination of primary tumors and
metastases. Stained sections were examined and photo-
graphed using an Olympus Vanox-T microscope and an
Olympus U-PMTVC CCD camera. Blood from control
and tumor bearing animals was collected by cardiac punc-
ture and analyzed by the Pathology Department at Tufts
University Cummings School of Veterinary Medicine
using standard hematological procedures.
Results
Characteristics of luciferase-expressing 4T1 cell lines
The luciferase-expressing 4T1-12B cell line was cloned
from 4T1 cells co-transfected with vectors encoding firefly
luciferase and puromycin drug resistance. The level of
luciferase expression is high enough to allow imaging of
as few as 10 cells in vitro using a Xenogen IVIS 200 biopho-
tonic imager; the cells are fully resistant to inclusion of 10
μg/ml of puromycin in the culture medium. The modified
cell line displayed a doubling time of 12 hours in culture
and a plating efficiency of 34%. Expression of luciferase
persisted when the cells were cultured for extended peri-
ods (> 2 months) in the absence of selective pressure, a
characteristic critical for reliable quantitation of tumor
growth and metastasis in vivo.
Imaging of a representative female BALB/c mouse six
weeks after mammary fat pad injection of 4T1-12B cells is
shown in Figure 1. At six weeks, primary tumors generally
reach a size of 1 cm3 or more and metastasis to the tho-
racic region is apparent in most animals. Imaging of vis-
ceral organs and hind limbs revealed metastases in several
organs including lungs, liver, bone and brain, sites
affected in human breast cancer.
A compilation of results for several animals injected with
the 4T1-12B line and several clones isolated from the
modified line after extended time in culture is shown in
Table 1. All animals injected with the 4T1-12B line dis-
played metastases in lungs at six weeks with substantial
numbers displaying metastasis to liver (5/6), spleen (3/6)
and bone (2/6). Metastases were occasionally found in
lymph nodes, brain, intestine, kidneys and adrenals.
Recloned sublines isolated from the 4T1-12B line dis-
played a similar spectrum of organ metastasis indicating
that most if not all of the cells in the preparation are tum-
origenic and metastatic and that the tumorigenic and met-
astatic properties of the cells are stable when cells are
expanded for as many as 20 to 30 generations in culture.
Generation of the 4T1-1V cell line involved transfection of
the 4T1 line with luciferase and puromycin vectors and a
vector containing a FLP recombinase targeting (FRT) site
contained within a lacZ-zeo fusion protein expression cas-
sette as described in MATERIALS AND METHODS. The
4T1-1V line was shown to contain a single site of integra-
tion of the FRT vector, to be readily susceptible to integra-
tion by FRT-containing targeting vectors, to stably express
luciferase, and to have metastatic characteristics similar to
the 4T1-12B line and its sublines. A plasmid containing a
Gateway cloning site for insertion of small hairpin siRNA
sequences was constructed from the FRT targeting vector,
pcDNA5/FRT, and tested for its ability to be incorporated
into the genome of the 4T1-1V line in an FRT-dependent
manner (Figure 2). A vector carrying a previously tested
sequence [13] encoding a small hairpin RNA for firefly
luciferase was shown to effectively inhibit expression of
luciferase in the 4T1-1V line.
Progression of tumor growth and metastasis in vivo
The results of a longitudinal study of primary tumor
growth and metastasis of the 4T1-1V line are shown in
Figure 3 and Table 2. Biophotonic imaging of animals
each week over a six week period after implantation of
4T1-1V cells in the abdominal no. 9 (or no. 4) mammary
fat pad revealed several previously unidentified character-
istics of the 4T1 model. Tumor growth at the site as meas-
ured by biophotonic imaging was found to occur in aBMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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Imaging of animals and organs at six weeks Figure 1
Imaging of animals and organs at six weeks. 4T1-12B cells (106) were implanted into the mammary fat pad of a normal 
female BALB/c mouse. After six weeks the whole animal and organs were imaged as described in MATERIALS AND METH-
ODS. The relationship between color and light intensity in arbitrary units (counts) for the whole animal images is given by the 
color bar at the right side of the figure.BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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biphasic fashion with rapid growth during the first two
weeks, regression between weeks 2 and 4, and increased
growth again in weeks 5 and 6 (Fig. 3, Top Panels). Metas-
tasis became apparent in the thoracic region and lower
limbs in weeks 5 and 6 of the second growth phase
although metastasizing cells probably seeded these sites
earlier [8,9]. Examination of light emission from organs
removed from the animals at week 6, revealed a spectrum
of organ metastasis similar to that observed for the 4T1-
12B line.
Further analysis revealed that biphasic growth at the pri-
mary site was related to immune system function. The
regression that was observed in weeks 2 through 4 in nor-
mal BALB/c mice was associated with necrosis and infil-
tration of leukocytes (Fig. 3, Bottom Right Panel).
Biphasic tumor growth did not occur in athymic nude or
SCID BALB/c mice (Fig. 4) suggesting involvement of an
acquired immune response in the effect. Antibodies
directed against multiple 4T1 cell antigens were found in
the sera of mice at week 6 (data not shown) further sup-
porting involvement of an acquired immune system
response in the regressive process.
Imaging of animals and organs at various times after
introduction of 4T1-1V cells in the fat pad revealed a clear
progression of metastasis first to lungs (beginning around
3 weeks) and later to liver, bone and spleen (weeks 3–6)
with occasional metastasis to brain, heart and intestines at
the later times (Table 2). Tumor cells were detected in
lymph nodes adjacent to primary tumors and elsewhere
in the animal consistent with previous studies suggesting
that 4T1 cells metastasize via the lymphatic system as well
as hematogenously [9,12].
The results of histological examination of metastases at
selected times and sites are shown in Figure 5. In lungs
and kidneys metastases were found within or in close
proximity to afferent vessels and in most cases appeared
infiltrative. In adrenals and liver metastases were more
localized, often appearing spherical in nature. Metastasis
to bone was prevalent throughout the skeletal system
including skull, ribs, sternum, and limbs. Bone-associated
osteoclasts were often observed in areas adjacent to bone
metastases indicating increased osteoclastogenesis and
elevated degradation of bone in these areas (Fig. 6).
A progressive increase in hematopoiesis was observed
throughout the 6 week time course as primary tumors
progressed and metastases developed at distant sites. This
was evidenced by increasing levels of circulating neu-
trophils and other leukocytes (Table 3) and by enlarge-
ment of the spleen and liver resulting from
extramedullary hematopoiesis that developed in these
organs (Figs. 7 and 8). Extramedullary hematopoiesis was
apparent by week 2 when primary tumors began to regress
and continued to increase until death ensued between
weeks 6 and 8. Immature myelocytic cells (Band N) were
found in the circulation at week 4. The histology of spleen
and liver and the composition and levels of circulating
leukocytes are consistent with expansion of granulocyte
lineages with circulating leukocytes reaching leukemia-
like levels by the end of the observation period (6 weeks).
Genes associated with the 4T1 metastatic phenotype
Gene expression analysis was carried out on the 4T1 cell
line and two of its sibling lines, 67NR and 168FARN to
identify expression differences associated with the 4T1
metastatic phenotype. Both of the sibling lines are non-
metastatic when introduced orthotopically into BALB/c
mice [9]. The 67NR line displays little if any dissemina-
tion from the primary site, whereas the 168FARN line dis-
plays dissemination to lymph nodes, but not to blood or
distant organs [9]. Using Illumina MouseRef-8 BeadChip
arrays, multiple replicates, and carefully controlled cul-
ture conditions, highly significant (p < 0.0001) expression
data for differences as low as 1.2-fold were achieved. Of
the 24,048 genes represented on the arrays, 1.8% or 430
genes (347 annotated) differed by 2-fold or more in the
4T1 line relative to the other two lines (Fig. 9). The
median false discovery rate for these genes was less than 1
in 500. The majority of all 2-fold differences were found
to be significant (p > 0.0001) for both the 4T1/67NR
(66.4%) and 4T1/168FARN (98.7%) comparisons. These
results indicate a very high level of confidence in the
genelists that were produced from the data.
Table 1: Summary of sites of metastasis for 4T1-12B1
Cell Line Primary Lungs Spleen Liver Bone Other
4T1-12B line 6(6)2 6(6) 3(6) 5(6) 2(6) Brain 1(6)
Intestine 1(6)
Kidney 1(6)
4T1-12B recloned lines (5) 10(10) 8(10) 2(10) 3(10) 6(10) Intestine 3(10)
Kidney 1(10)
1Cells were introduced into fatpads of normal female BALB/c mice and imaged after 5–6 weeks as described in MATERIALS AND METHODS.
2Number of animals positive (total number of animals)BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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Targeting shRNAs and cDNAs to FRT site in 4T1-1V Figure 2
Targeting shRNAs and cDNAs to FRT site in 4T1-1V. (Top) The diagram shows the results of FLP recombinase-
dependent insertion of the FRT targeting vector carrying a cDNA and/or siRNA, into the genome. The promoter driving 
expression of the lacZ-zeo fusion protein before insertion drives expression of the hygromycin resistance gene after insertion 
allowing hygromycin selection of cells that had undergone targeted insertion of the vector. (Bottom) Cells were cotrans-
fected with the indicated vector and an expression vector encoding FLP recombinase. Cell pools and clones were isolated from 
the transfected cells and assayed for luciferase expression as described in MATERIALS AND METHODS. Light emission in 
arbitrary units per milligram of cell protein is shown for pools and clones transfected with empty targeting vector or targeting 
vector encoding luciferase shRNA. Error bars represent standard deviations for empty vector (n = 6) and luciferase siRNA 
vector (n = 7) transfected clones.
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Ingenuity Pathway Analysis (IPA) of genes differentially
expressed in 4T1 relative to the two non-metastatic lines
revealed significant association with cancer and other dis-
eases including hematological and inflammatory disease
(Table 4), findings consistent with the high level of
inflammation and hematopoiesis observed for the 4T1
lines in vivo. Also consistent with the 4T1 metastatic phe-
notype was association with cell movement, cell signal-
ing, cell growth, proliferation and death, and cell to cell
signaling and interaction (Table 4). Many of the expres-
Progression of tumor growth and metastasis Figure 3
Progression of tumor growth and metastasis. (Left) 4T1-1V cells (106) were introduced into mammary fat pads of nor-
mal female BALB/c mice and the animals were imaged on a weekly basis for six weeks. The animals were sacrificed at the end 
of the sixth week and organs and hind limbs were removed and imaged. Images for two representative animals are shown. 
(Top Right) Quantitation of light emission from primary tumor over the six week period. (Bottom Right) H&E staining of a 
section from a primary tumor illustrating a central area of necrosis infiltrated by leukocytes and neoplastic cells at the periph-
ery. The neoplastic cells are poorly differentiated and characterized by the presence of large hyperchromatic nuclei and rela-
tively small amount of cytoplasm. Identifiable neutrophils and mast cells that appear to be located extravascularly were 
observed in non-necrotic areas of the tissue.BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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Table 2: Kinetics and extent of metastasis for 4T1-1V1
Time after injection (days) Primary Lungs Spleen Liver Bone Kidney/Adrenals Other
8–14 3(3)2 -- - - - -
15–21 3(3) 1(3) - - - - -
22–28 5(5) 5(5) 1(5) 2(5) 0(5) 1(5) Intestine 1(5)
29–35 7(7) 7(7) 2(7) 6(7) 3(7) 2(7) Intestine 1(7)
36–42 7(7) 7(7) 5(7) 6(7) 6(7) 2(7) Brain 1(7)
Heart 1(7)
1Cells were introduced into fatpads of normal female BALB/c mice and imaged at the indicated times as described in MATERIALS AND METHODS.
2Number of animals positive (total number of animals)
Involvement of immune system in primary tumor growth Figure 4
Involvement of immune system in primary tumor growth. 4T1-12B cells (106) were implanted into the mammary fat 
pad of two normal (❍), athymic nude () and SCID () BALB/c mice and imaged weekly as described in MATERIALS AND 
METHODS. Average luminescence +/- sd for each time point is plotted.
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Metastasis to lungs, kidneys, adrenals and liver Figure 5
Metastasis to lungs, kidneys, adrenals and liver. (A) Lung at 3 weeks showing metastases adjacent to blood vessels. (B) 
Tumor cells in a major vessel of the kidney at week 6. Note infiltration of tumor cells into kidney parenchyma (arrowhead, left 
panel). (C) Tumor-laden adrenal gland at 6 weeks with multiple spherically-shaped metastases. (D) Large metastasis on the sur-
face of the liver at week 6. Note abnormal appearance of liver parenchyma and high levels of leukocytes in parenchyma (arrow-
heads, right panel) and sinusoids (arrows, right panel). Specimens were obtained from the experiment described in Figure 3.BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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sion differences that characterize the 4T1 phenotype
including those known to be involved in metastasis and/
or tumorigenesis are listed in Additional File 1.
Genes differentially expressed in 4T1 were categorized
with respect to cellular location and function (Fig. 10).
Among the genes are substantial numbers involved in cell
adhesion, migration, angiogenesis, and extracellular
matrix modification; cytoskeleton function; cell prolifera-
tion, apoptosis and survival; cellular metabolism; and
inflammation and immune response. Altered expression
of several transcription factors and genes involved in chro-
matin modification that regulate these processes were also
observed. Elevated expression of genes associated with
tight junctions (Cldn3, Cldn4, Cldn7 and Tjp2), adherins
junctions (Cdh1 and Vil1) focal adhesions (Itga3, Itga6
and Lama5), and intermediate filaments (Krt1-18 and
Krt2-7) indicate that the 4T1 line has greater epithelial
character than the non-metastatic lines. An increased pro-
pensity for extracellular matrix (ECM) remodeling is sug-
gested by elevated expression of matrix
metalloproteinases (Mmp3, Mmp9 and Mmp13), uroki-
nase-type plasminogen activator (Plau) and secreted pro-
tease inhibitors (Serpina3g, Serpin2 and Lcn2).
Signaling pathways associated with phenotype
Several signaling pathways appear to be activated in 4T1
cells (Fig. 11). Most conspicuous is activation of the Jak/
Stat pathway as indicated by elevated expression of Jak2
and Stat1, decreased expression of Socs1 and increased
expression of several Stat target genes (Myc, Irf1, Igsf3g
and Usp20) (Fig. 11A). Also conspicuous is activation of
Metastasis to bone Figure 6
Metastasis to bone. (Top Left) Metastasis near joint between femur and tibia at week 6. Note extensive degradation of 
bone adjacent to the upper surface of the tumor. (Top Right) Interface between tumor and bone at higher magnification. 
Note osteoclasts (arrowheads) lining the lower surface of the bone. (Bottom Left and Right) Femoral metastasis within the 
joint itself at low and high resolution at 6 weeks. Specimens were obtained from the experiment described in Figure 3.
A – Bone (week 6)
B – Bone (week 6)BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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p38 MAPK (Mapk12) as indicated by increased expression
of CCAAT/enhancer binding protein beta (Cebpb) and
high levels of expression of Cebpb/NFκB target cytokines
(Ccl5/RANTES, Csf2, Csf3 and Tslp) and acute phase pro-
teins (Saa3, C3 and Lcn2). Increased expression of TIAM1
(Tiam1) and genes in the IL-1 and TNF-α pathways (Il1a,
Tnfrsf19, Traf1, Card10) suggest that these pathways,
which are known to activate p38 MAPK, may be involved
in the expression of Cebpb/NFκB targets. Targets of p38
MAPK are known to activate the Jak/Stat pathway (Fig. 11)
so it is therefore likely that p38 MAPK signaling is respon-
sible for the activation of the Jak/STAT pathway in these
cells. Elevated expression of Wnt (Wnt10a) and its recep-
tors (Fzd6 and Fzd7) suggests activation of the Wnt path-
way (Fig. 11B). While some Wnt pathway targets (Myc
and Plau) displayed elevated expression, other known tar-
gets (c-jun, cycD and Fosl1) did not. It may be that the
purpose of altered expression of Wnt pathway ligand and
receptors is to increase β-catenin levels to support junc-
tional complexes that are more prevalent in these cells.
Both the canonical and the non-canonical Wnt pathway
are known to play an important role in establishment and
maintenance of cellular junctions [16]. Finally, 4T1 dis-
played significantly reduced levels of CDK2-associated
protein 1 (CDK2ap1), p53 and two p53 targets, cyclin-
dependent kinase inhibitor p21 (Cdkn1a) and cyclin G
(Ccng1) (Fig. 11C). These alterations would be expected
to accelerate the early phase of the cell cycle (G1 → S) and
attenuate the DNA damage response. Expression of a third
p53 target, Gadd45, was elevated. Gadd45 is regulated by
hypoxia and glucose deprivation as well as by p53. Ele-
vated expression of several genes known to be sensitive to
hypoxia and/or glucose deprivation (Pfkfb3, Vegfc, Flt1
and Trib3), suggest that elevated expression of Gadd45
may be due to these factors and that 4T1 cells exist in a
state of stress or pseudo-stress even under optimal culture
conditions.
Alterations related to tumor microenvironment
A variety of factors produced at elevated levels by 4T1 cells
are secreted cytokines, chemokines, acute phase proteins
and proteases that interact locally and systemically with
the host to produce, recruit and activate cells of hemat-
opoietic origin capable of remodeling the tumor microen-
Table 3: Circulating white cell analysis1
WBC Population Control (n = 1) Week 1 (n = 3) Week 4 (n = 4)
WBC 5.3002 4.200 56.210
4.200 66.000
2.800 15.700
134.000
Seg N 0.424 (8%)3 1.386 (33%) 34.850 (62%)
0.546 (13%) 48.840 (74%)
1.148 (41%) 8.164 (52%)
99.160 (74%)
Band N - - 3.373 (6%)
- 3.962 (6%)
- 0.157 (1%)
10.720 (8%)
Metamyelocytes - - 0.562 (1%)
- 0.660 (1%)
--
2.680 (2%)
Lymphocytes 4.823 (91%) 2.772 (66%) 16.863 (30%)
3.654 (87%) 10.560 (16%)
1.624 (58%) 6.594 (42%)
20.100 (15%)
Monocytes - - -
- 1.320 (2%)
- 0.314 (2%)
-
Eosinophils 0.053 (1%) 0.042 (1%) 0.562 (1%)
- 0.660 (1%)
0.028 (1%) 0.471 (3%)
1.340 (1%)
1Whole blood was collected by cardiac puncture at the indicated time after orthotopic introduction of tumor cells as described in MATERIALS 
AND METHODS.
2Total number of WBC/ml blood in millions for each animal tested.
3Number of cells/ml blood in millions for each animal tested (% of total WBC for animal)BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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vironment and facilitating tumor cell dissemination.
These factors and their expected effects on the tumor
microenvironment are depicted in Figure 11D. Two
important modulators of endothelial cell function pro-
duced by 4T1 cells are vascular endothelial growth factor
C (Vegfc) and angiopoietin 2 (Agpt2). VEGF-C interacts
with VEGF receptors on endothelial cells to stimulate ang-
iogenesis and lymphangiogenesis when existing vessels
are destabilized. Angiopoietin 2 destabilizes vessels by
antagonizing the stabilizing effects of angiopoietin 1.
Together, these factors would be expected to induce both
angiogenesis and lymphangiogenesis, increase tumor vas-
cularization and provide routes of escape of tumor cells.
The inhibitory effect of semaphorin 3F (Sema3f) on ang-
iogenesis would be expected to shift vessel development
toward lymphangiogenesis. Angiopoietin 2 and VEGF-C
also serves as chemotactic factors for recruitment of circu-
lating monocytes and macrophages.
Macrophages and other cells recruited to the tumor are
produced in the bone marrow and other tissues by hemat-
opoiesis. Colony stimulating factors GM-CSF (Csf2) and
G-CSF (Csf3) produced and secreted by 4T1 cells stimu-
late hematopoiesis along the myeloid lineages and are
likely to be responsible for the high levels of hematopoie-
sis and circulating leukocytes observed when tumors from
4T1 cells are established in vivo [17]. Several factors pro-
duced by 4T1 cells are known to play a role in recruitment
of hematopoietic cells to tissues. RANTES (Ccl5) is chem-
otactic for mast cells [18] and fragments generated auto-
catalytically from complement C3 (C3) are capable of
stimulating mast cells to release TNFα, histamine,
Hematopoiesis in spleen Figure 7
Hematopoiesis in spleen. Spleen at 1 (Top) and 6 (Bottom) weeks. Spleen appears normal at week 1. Extensive 
extramedullary hematopoiesis is apparent at week 6 as evidenced by the presence of megakaryocytes (arrow heads). Speci-
mens were obtained from the experiment described in Figure 3.
A – Spleen (week 1)
B – Spleen (week 6)BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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Hematopoiesis in liver Figure 8
Hematopoiesis in liver. Liver at 1 (Top), 2 (Middle) and 6 (Bottom) weeks. Liver appears normal at week 1. Islands of 
extramedullary hematopoiesis are seen at week 2 and extensive hematopoiesis throughout the liver is apparent at week 6. 
Note increased proportion of nucleated cells in blood vessels at weeks 2 and 6. Specimens were obtained from the experiment 
described in Figure 3.
A – Liver (week 1)
B – Liver (week 2)
C – Liver (week 6)BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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cytokines and other factors that can act to recruit a wide
range of cells including monocytes, dendritic cells, neu-
trophils, eosinophils and lymphocytes. RANTES (Ccl5) is
also known to stimulate secretion of interleukin 8 (Il8)
from macrophages [19]. Interleukin 8 is also released by
stromal fibroblasts in response to interleukin 1α pro-
duced by 4T1 cells. Interleukin 8 along with chemokines
(Cxcl6, Cxcl1) released by 4T1 are chemotactic for neu-
trophils [20,21]. Finally, matrix metalloproteinases pro-
duced by macrophages, fibroblasts and neutrophils
recruited to the tumor would add to the already high lev-
els of matrix metalloproteinases released by the tumor
cells themselves thereby creating a high potential for dis-
solution of matrix and cell-matrix interactions, a condi-
tion likely to facilitate tumor cell invasion and metastasis.
Previous studies have indicated that populations of
immature myeloid cells called myeloid derived suppres-
sor cells (MDSC) are induced by tumors and that these
cells facilitate tumor growth and metastasis by suppress-
ing the immune response [22]. Ectopic expression of
interleukin 1β in 4T1 cells has been shown to increase
MDSC levels and stimulate growth and metastasis of 4T1
tumors in vivo [23]. Because interleukin 1α rather than
interleukin 1β is the predominant form of interleukin 1
produced by 4T1 cells, and because the two cytokines
have similar biological activity, it is likely that expression
of interleukin 1α by 4T1 is involved in production of
MDSC and their effects on growth and metastasis of 4T1
in vivo.
Discussion
Here we report on the generation of two clonal 4T1 cell
lines (4T1-12B and 4T1-1V), both of which stably express
firefly luciferase at a high level in the absence of selective
pressure, and one (4T1-1V) which was also modified by
addition of an FRT site in its genome. These lines were
shown to have metastatic characteristics similar to the
parental 4T1 line displaying metastasis to bone, lungs,
and liver and brain organs primarily affected in human
breast cancer. The ability to image the cells ex vivo with
Genes with altered expression in 4T1 vs. 67NR and  168FARN Figure 9
Genes with altered expression in 4T1 vs. 67NR and 
168FARN. Genes with 2-fold expression differences for 
4T1 vs. 67NR and 4T1 vs. 168FARN were determined as 
described in MATERIALS AND METHODS. Genes in the 
intersection between the two comparisons are those consid-
ered to be associated the metastatic phenotype of the 4T1 
cell line. Genes in the intersection represent 1.8% of the 
total genes analyzed, 52% of genes differentially expressed 
for 4T1 vs. 67NR and 45% of those differentially expressed 
for 4T1 vs. 168FARN.
Table 4: Ontological analysis1
p-value # molecules
Diseases and Disorders
Cancer 5.07E-14-5.72E-04 100
Hematological Disease 1.80E-08-5.72E-04 51
Connective Tissue Disorders 3.41E-08-1.44E-04 35
Dermatological Diseases and Conditions 1.75E-07-5.37E-04 41
Inflammatory Disease 8.81E-07-5.51E-04 38
Molecular and Cellular Functions
Cell Movement 1.18E-15-5.72E-04 69
Cell Signaling 1.30E-13-2.04E-04 106
Cell Death 1.67E-13-5.32E-04 96
Cellular Growth and Proliferation 1.03E-12-5.79E-04 111
Cell to Cell Signaling and Interaction 1.94E-08-5.19E-04 63
1304 annotated gene were included in the analysisBMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
Page 16 of 20
(page number not for citation purposes)
4T1 genes categorized by cellular location and function Figure 10
4T1 genes categorized by cellular location and function. Genes associated with the 4T1 metastatic phenotype that fall 
into the categories shown are listed in the figure. Genes shown in red are elevated in 4T1 and genes shown in blue reduced in 
4T1. The blue line to the right of middle represents the plasma membrane with genes falling to the right of it representing 
secreted genes. The blue rectangle to the left of middle represents intracellular membranes and genes falling inside the rectan-
gle are genes located within intracellular organelles.BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
Page 17 of 20
(page number not for citation purposes)
Pathways involved in metastatic phenotype of 4T1 Figure 11
Pathways involved in metastatic phenotype of 4T1. Pathways shown are based on known Kegg pathways with modifica-
tions based on recent literature relating 4T1 phenotype genes to these pathways. Red and blue boxes represent genes that are 
up-regulated or down-regulated by > 2-fold, respectively. Red arrows represent chemotaxis. Numbers outside the boxes give 
the higher of the two ratios for expression in 4T1 relative to the non-metastatic 67NR and 168FARN lines.BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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high sensitivity allowed detection and quantitation of
metastases in affected organs more effectively than has
been possible previously. Luciferase-expressing 4T1 vari-
ant cell pools and lines with increased propensity for
metastasis to brain, liver, and bone have recently been iso-
lated (to be published elsewhere). These variants will fur-
ther expand the repertoire of syngeneic models available
for the study of late stage breast cancer.
An acquired immune response was found to play an
important role in regulating 4T1 tumor growth and
metastasis. 4T1 tumors established in normal BALB/c
mice displayed a substantial loss of tumor cells beginning
2–3 weeks after introduction. This effect was not apparent
in BALB/c nude and BALB/c SCID mice, in which 4T1 cells
in tumors proliferated rapidly and continuously. Antibod-
ies directed against several 4T1 antigens were detected in
sera from normal tumor-bearing BALB/c mice further sup-
porting the involvement of an acquired immune response
to the cells. Myeloid derived suppressor cells (MDSC)
which are known to be induced in 4T1 tumor-bearing
mice are likely to be involved in establishment and main-
tenance of 4T1 tumors by attenuating the immune
response to allow survival of the tumor in weeks 3–4 and
re-emergence of tumor growth in weeks 5–6. Further work
will be required to determine the actual role that MDSC
and other immune system components play in regulating
the growth and survival of 4T1 tumors.
Metastasis of 4T1 tumors is associated with extensive
necrosis and inflammation within the primary tumor and
hematopoiesis in several mouse organs including spleen
and liver. Elevated hematopoiesis has recently been
reported for the 4T1 model [17,24]. Whether or not a
causal relationship exists between these processes and
metastasis remains to be demonstrated although two
observations suggest that there may be such a connection.
First, the extent of necrosis is greater in 4T1 tumors than
those derived from less metastatic sibling cell lines (67NR,
168FARN) as indicated by the occurrence of large areas of
visible necrosis in the 4T1 tumors. Second, a causal rela-
tionship between inflammation and metastasis is sup-
ported by the inhibitory effect of the COX-2 inhibitor, SC-
236, on metastasis of 4T1 after primary tumor excision
[25]. Inflammation is known to have a positive effect on
metastasis in several systems [26-28] and is likely to have
a pro-metastatic effect in this system as well.
Inflammation in metastatic tumors is generally thought to
result from signals produced by dying cells and ECM frag-
ments in areas of insufficient vascularization [29]. A note-
worthy finding of this study is that 4T1 tumor cells, when
cultured under optimal growth conditions, produce a
wide range of factors capable of inducing production,
recruitment and activation of inflammatory cells. These
factors include colony stimulating factors GM-CSF (Csf2)
and G-CSF (Csf3); cytokines Ccl5, Cxcl1, Cxcl6 and Tslp;
angiogenic factors Agpt2 and Vegfc; and acute phase pro-
teins Saa3, C3, and Lcn2. While this does not preclude the
involvement of cell death in initiating an inflammatory
response in the tumor, it does suggest that the tumor cells
themselves may play a more direct and active role in
directing pro-metastatic inflammatory processes than pre-
viously envisioned.
The methodology used in this study for analysis of gene
expression yielded highly significant data characterizing
the 4T1 metastatic phenotype. The majority of genes that
differed by more than 2-fold in 4T1 relative to the two
non-metastatic sibling lines examined displayed an excep-
tionally high level of significance (p < 0.0001) and
genelists obtained at this level of significance displayed
very low false positive rates. The statistics argue that the
results obtained provide a relatively complete and accu-
rate picture of expression differences associated with the
4T1 phenotype. The high level of accuracy and reproduci-
bility that was achieved is attributed to use of the Illumina
BeadChip platform and analysis of cells cultured under
carefully controlled growth conditions that minimize dif-
ferences between biological replicates. The data obtained
from this study provide detailed information regarding
the genes and pathways involved in breast cancer progres-
sion for this model and will be particularly useful for fur-
ther analysis of the pathological processes responsible for
progression to a metastatic phenotype.
Unlike many cell lines used as xenograft models, sub-
clones of the 4T1-12B cell line that had undergone more
than 20 doublings were found to be homogeneous with
respect to metastatic properties. These cells also display a
high plating efficiency and no visibly apparent differenti-
ation in culture or in vivo. Thus, the cells resemble stem
cells found in populations of cell lines such as MCF7 [30]
in that they are self renewing, but differ in that they do not
appear to differentiate. While more work is need to deter-
mine the basis for this property, the characteristic has util-
ity for studies aimed at determining gene function since
clonal lines in which a specific genes have been over-
expressed or knocked down can be expected to retain the
properties of the parental line from which they were
derived. In this regard, the FRT site in the 4T1-1V line will
be useful for production of isogenic lines for analysis of
gene function.
Conclusion
In conclusion, this study provides basic information for
those interested in using two imagable 4T1 breast cancer
models developed in this laboratory. Several characteris-
tics of these models make them particularly attractive for
the study of late stage breast cancer. First and foremost,BMC Cancer 2008, 8:228 http://www.biomedcentral.com/1471-2407/8/228
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because of their syngeneic nature, they provide a highly
physiologic system suitable for analysis of innate and
acquired immune system roles in tumor growth and
metastasis. The relatively complete gene expression data
provided offer numerous avenues for further study of the
molecular and pathologic basis for these and other proc-
esses related to late stage breast cancer. To our knowledge,
the 4T1 model is the only system that has the capacity to
metastasize to all organs affected in breast cancer in
humans when introduced orthotopically. For this reason,
and because of the ease of use and reproducibility that can
be achieved, these imagable models provide ideal systems
for determining anti-metastatic effects of cancer drugs and
therapeutic regimens and is well suited for investigating
the molecular, cellular and pathologic basis for metastasis
to specific organs and tissues.
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